Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR1E | P28566 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29196319 | 0.86 | ALDH1A1 (0.46) | POLBATMCA2ALDH1A1KMT2A | |
| SCHEMBL1034882 | 0.84 | CA2 (0.69) | HTR7POLBATMCA2ALDH1A1 | |
| SCHEMBL31114400 | 0.84 | CA2 (0.69) | HTR7POLBATMCA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10772018 | 0.83 | CA2 (0.67) | HTR7POLBATMCA2ALDH1A1 | |
| SCHEMBL8253257 | 0.82 | RXRA (0.42) | HTR7KMT2AMEN1HTR1AHTR1D | |
| SCHEMBL13111719 | 0.81 | CA2 (0.50) | POLBATMCA2ALDH1A1KMT2A | |
| SCHEMBL5024938 | 0.80 | TTR (0.55) | POLBATMCA2ALDH1A1KMT2A | |
| SCHEMBL6353922 | 0.80 | CA2 (0.48) | POLBATMCA2ALDH1A1KMT2A | |
| SCHEMBL31681724 | 0.80 | TTR (0.55) | POLBATMCA2ALDH1A1KMT2A | |
| SCHEMBL5026284 | 0.80 | CA2 (0.48) | POLBATMCA2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441704-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | ALMIRALL, S.A. (ES) | 2021-06-24 | — | — | US | disclosed |
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| US-7592345-B2 | Piperazine and [1,4]diazepan derivatives as NK antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685727-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | HTR7 818/4885POLB 941/4885ATM 2288/4885 |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | HTR7 818/4885POLB 941/4885ATM 2288/4885 |
| US-12441704-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | HTR7 818/4885POLB 941/4885ATM 2288/4885 |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | HTR7 153/4885POLB 2554/4885ATM 1740/4885 |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | HTR7 818/4885POLB 941/4885ATM 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.